Clinical Trial Update: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

View source ↗

Summary

LAPIX Therapeutics announced completion of an observational biomarker study in multiple sclerosis, covering relapsing-remitting and progressive disease forms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: LAPIX Therapeutics Inc. | Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive | Status: COMPLETED